Welcome to our dedicated page for Firefly Neuroscience SEC filings (Ticker: AIFF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Firefly Neuroscience, Inc. (NASDAQ: AIFF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed technology issuer, Firefly submits annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy materials on Schedule 14A that describe its business, financial condition, governance, and capital structure.
For an AI company focused on EEG- and ERP-based brain analytics software, filings such as the Form 10-K and Form 10-Q detail Firefly’s BNA™ platform, its concentration in the Software – Application industry, its revenue sources in North America, and risk factors related to product development, regulatory matters, and commercialization. Current reports on Form 8-K, including those describing annual meeting results and changes to authorized share capital, provide timely information on material events, shareholder votes, and corporate actions.
Definitive proxy statements (DEF 14A) offer insight into Firefly’s governance practices, director elections, equity incentive plans, and proposals to amend its certificate of incorporation or long-term incentive plan share limits. These documents explain how the board oversees the company’s AI-driven brain health strategy and how equity awards are structured for directors, executives, and employees.
On Stock Titan, each new Firefly filing is captured as it becomes available from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as segment descriptions, updates related to the FDA-cleared BNA™ technology, changes in authorized shares, and outcomes of shareholder meetings. Users can also review ownership and governance information, and locate Form 4 insider transaction reports when they are filed, to see how officers and directors transact in AIFF stock. This page is a centralized resource for investors who want to understand Firefly’s regulatory history and the formal disclosures that support analysis of its AI-based brain analytics business.
Firefly Neuroscience, Inc. entered into an at-the-market equity offering agreement with Konik Capital Partners, LLC, allowing the company to sell shares of common stock with an aggregate offering price of up to $7,434,266 on Nasdaq or other markets. Konik will act as sales agent or principal, earning a 2.0% commission on gross proceeds and reimbursement of specified legal and diligence costs. The shares are being offered under Firefly’s effective Form S-3 shelf registration and a February 3, 2026 prospectus supplement, and the company currently intends to use net proceeds for working capital and general corporate purposes.
Separately, a wholly owned subsidiary amended the employment agreement of Chief Technology Officer Gil Issachar, replacing his automatic annual bonus with eligibility for a discretionary annual bonus of up to one month of gross salary and providing for payment of outstanding bonuses accrued through December 31, 2025.
Firefly Neuroscience, Inc. is registering an at-the-market offering of its common stock with a maximum aggregate offering price of $7,434,266, to be sold from time to time through Konik Capital Partners, a division of T.R. Winston and Company, as sales agent.
The company’s common stock trades on the Nasdaq Capital Market under the symbol AIFF, with 14,214,082 shares outstanding as of February 3, 2026. At a recent price of $0.86 per share, this facility could significantly increase the share count over time, depending on actual sale prices.
Sales will be made in ordinary brokerage transactions deemed “at-the-market,” and the sales agent will earn a 2% commission on gross proceeds. Firefly plans to use any net proceeds primarily for working capital and general corporate purposes, while cautioning that investing in its stock involves a high degree of risk, including potential dilution and share price volatility.
Firefly Neuroscience, Inc. shareholder group files an exit Schedule 13D amendment after selling stock. A group including Windsor Private Capital LP, WPC entities, Jordan Kupinsky, HJRK Holdings, Rocco Marcello and John Cundari sold an aggregate of 147,300 common shares between December 31, 2025 and January 30, 2026.
After these open-market sales, Windsor-related entities each report beneficial ownership of 605,421 common shares, or 4.5% of Firefly Neuroscience’s 13,492,928 shares outstanding as of December 2, 2025. Jordan Kupinsky reports 674,181 shares, or 5.0%, including holdings through Windsor and HJRK Holdings. The group states it has ceased to be beneficial owner of more than 5% of the company’s common stock.
Firefly Neuroscience, Inc. is registering up to $250,000,000 of securities under a mixed shelf offering. The company may periodically sell common stock, preferred stock, debt securities, warrants, subscription rights, and units, with specific terms and prices to be set in future prospectus supplements. Firefly’s common stock trades on the Nasdaq Capital Market under the symbol “AIFF,” and the last reported sale price on December 2, 2025 was $1.61 per share. As of that date, there were 13,492,928 shares of common stock outstanding. The company currently expects to use any net proceeds for treasury strategy, working capital and general corporate purposes while continuing to commercialize its AI-driven brain health assessment products.
Firefly Neuroscience, Inc. is registering 317,820 additional shares of common stock for issuance under its amended 2024 Long-Term Incentive Plan. This increases the pool of equity available for employee, executive and director compensation following stockholder approval of an amendment to the plan on October 27, 2025. Previously, 154,750 shares were registered for issuance and 678,583 shares issued under the plan were registered for reoffer and resale on an earlier Form S-8.
The filing also includes a revised reoffer prospectus covering up to 1,048,963 shares that may be sold from time to time by certain employees, executive officers and directors, from which the company will not receive any proceeds. Firefly develops FDA-510(k) cleared AI-driven EEG tools such as its BNA and Evox systems to support diagnosis and management of mental and neurological disorders. Its common stock trades on Nasdaq under the symbol AIFF, with a last reported sale price of $1.60 per share on November 13, 2025. Independent auditors’ reports incorporated by reference note substantial doubt about the company’s ability to continue as a going concern.
Firefly Neuroscience (AIFF) reported Q3 2025 results. Revenue rose to $388 thousand, driven mainly by the Evoke acquisition, yielding gross profit of $146 thousand. Operating loss was $2.656 million and net loss was $2.639 million for the quarter. For the nine months, revenue reached $730 thousand and net loss was $17.402 million, including a $9.369 million loss from change in derivative fair value and a $1.353 million loss on settlement of a convertible note.
Cash was $4.325 million at September 30, 2025; net cash used in operating activities was $6.389 million for the nine months. The company completed the Evoke Neuroscience deal for $3.0 million in cash plus 857,142 shares (valued at $2.743 million) and contingent consideration of $478 thousand, recording $5.175 million of goodwill. Management disclosed that recurring losses and limited revenue raise “substantial doubt” about continuing as a going concern. Common shares outstanding were 13,482,511 as of November 6, 2025.
Firefly Neuroscience, Inc. (AIFF) reported final results from its 2025 annual meeting and a reconvened session. Stockholders elected two Class II directors and ratified Marcum Canada, LLP as auditor. They approved an amendment to the 2024 Long‑Term Incentive Plan to add 317,820 shares and adopt an annual increase equal to the lower of
At the reconvened meeting on
Firefly Neuroscience (AIFF) reported an insider equity grant. A company director received 73,892 deferred stock units (DSUs) on October 28, 2025 under the 2024 Long‑Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock. Following this transaction, the reporting person held 90,559 derivative securities on a direct ownership basis. The DSUs were reported at a $0.00 price.
Firefly Neuroscience (AIFF) reported a director equity award. On October 28, 2025, the reporting person received 49,262 deferred stock units (DSUs) under the 2024 Long‑Term Incentive Plan. These DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the award, the filing lists 65,929 derivative securities beneficially owned, held directly. The transaction was coded as an acquisition at a stated price of $0.00, consistent with a standard equity grant for board service.
Firefly Neuroscience, Inc. (AIFF) disclosed a Form 4 showing a director received 49,262 deferred stock units (DSUs) on October 28, 2025 under the Issuer's 2024 Long-Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the grant, 65,929 derivative securities were beneficially owned, held directly. The transaction price for the DSUs was $0.00.